Amneal Pharma Announces FDA Approval For Its Biosimilar Referencing Neulasta

Amneal Pharmaceuticals, Inc. (AMRX) announced the FDA has approved the company's Biologics License Application for pegfilgrastim-pbbk, a biosimilar referencing
Neulasta. The product will be marketed under the name FYLNETRA.

FYLNETRA was developed in collaboration with Kashiv Biosciences. It is used to treat neutropenia.

The company noted that this marks the third biosimilar approval Amneal received this year for products used in oncology. Amneal expects to launch these three products over the second half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT